Compare OGI & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OGI | MDWD |
|---|---|---|
| Founded | 2013 | 2000 |
| Country | Canada | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 218.5M | 238.5M |
| IPO Year | N/A | 2014 |
| Metric | OGI | MDWD |
|---|---|---|
| Price | $1.71 | $18.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $37.50 |
| AVG Volume (30 Days) | ★ 1.9M | 81.2K |
| Earning Date | 02-10-2026 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $186,075,713.00 | $20,932,000.00 |
| Revenue This Year | $20.38 | $15.89 |
| Revenue Next Year | $6.02 | $25.33 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 6.15 |
| 52 Week Low | $0.85 | $14.14 |
| 52 Week High | $2.24 | $22.51 |
| Indicator | OGI | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 47.53 | 55.25 |
| Support Level | $1.67 | $18.55 |
| Resistance Level | $1.76 | $18.86 |
| Average True Range (ATR) | 0.16 | 0.55 |
| MACD | -0.03 | -0.04 |
| Stochastic Oscillator | 28.67 | 58.52 |
Organigram Global Inc is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. It is is focused on producing high-quality cannabis for adult recreational consumers. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.